Should You Add PhaseBio Pharmaceuticals Inc (PHAS) Stock to Your Portfolio Wednesday?

Wednesday, October 26, 2022 01:55 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Add PhaseBio Pharmaceuticals Inc (PHAS) Stock to Your Portfolio Wednesday?

PhaseBio Pharmaceuticals Inc (PHAS) is near the bottom in its sector according to InvestorsObserver. PHAS gets an overall rating of 13. That means it scores higher than 13% of stocks. PhaseBio Pharmaceuticals Inc gets a 26 rank in the Healthcare sector. Healthcare is number 2 out of 11 sectors.

PHAS has an Overall Score of 13. Find out what this means to you and get the rest of the rankings on PHAS!

See Full PHAS Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With PhaseBio Pharmaceuticals Inc Stock Today?

PhaseBio Pharmaceuticals Inc (PHAS) stock is trading at $0.12 as of 1:54 PM on Wednesday, Oct 26, a decline of -$0.01, or -8% from the previous closing price of $0.14. The stock has traded between $0.12 and $0.13 so far today. Volume today is high. So far 2,424,245 shares have traded compared to average volume of 1,482,602 shares. Click Here to get the full Stock Report for PhaseBio Pharmaceuticals Inc stock.